A grading system based on severity of infection to predict mortality in allogeneic stem cell transplant recipients

Transplantation

Volumn 82, Issue 1, 2006, Pages 86-92

  Cordonnier, Catherine ^a   Maury, Sébastien ^a   Ribaud, Patricia ^b   Kuentz, Mathieu ^a   Bassompierre, François ^b   Gluckman, Eliane ^b   Chevret, Sylvie ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b SAINT LOUIS HOSPITAL   (France)

Author keywords

Hematopoeitic stem cell transplantation; Infection; Mortality

Indexed keywords

ANTIBIOTIC AGENT; CYCLOSPORIN A; GANCICLOVIR; IMMUNOGLOBULIN; METHOTREXATE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; CAUSE OF DEATH; CONTROLLED STUDY; COVARIANCE; CYTOMEGALOVIRUS INFECTION; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG DOSE REGIMEN; FEMALE; FUNGEMIA; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SEPSIS; ALLOTRANSPLANTATION; CLASSIFICATION; HOSPITALIZATION; MIDDLE AGED; STEM CELL TRANSPLANTATION;

ADULT; FEMALE; HUMANS; INFECTION; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 33747466043     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000225762.54757.f7     Document Type: Article

References (43)

1. The Immunocompromised Host Society: The Design, Analysis, and Reporting of Clinical Trials on the Empirical Antibiotic Management of the Neutropenic Patient. J Infect Dis 1990; 161: 397-401.
2. Hughes WT, Armstrong D, Bodey GP, et al. Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Clin Infect Dis 1997; 25: 551.
3. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34(1): 7-14.
4. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HLAmatched sibling donors. Transplantation 1974; 18(4): 295.
5. Rowlings PA, Przepiorka D, Klein D, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glücksberg grade. Br J Haematol 1997; 97: 855.
6. Martin PJ, Schoch G, Gooley T, et al. Methods for assessment of graft-versus-host disease. Blood 1998; 92(9): 3479.
7. Cordonnier C, Chevret S, Legrand M, et al. Should immunoglobulin therapy be used in allogeneic stem cell transplant? A randomized, double-blind, dose-effect, placebo-controlled, multicenter trial. Ann Intern Med 2003; 139: 8.
8. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. I: Michelson S, Plotkin S eds. Multidisciplinary Approach to Understanding Cytomegalovirus Disease. Amsterdam: Experta Medica International Congress Series 1993; 233-237.
9. Brun-Buisson C, Doyon F, Carlet J, et al. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996; 154: 617.
10. Elting LS, Rubenstein EB, Rolston KVI, et al. Outcomes of bacteremia in patients with cancer and neutropenia: Observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25: 247-259.
11. Verfaille C, Weisdorf D, Haake R, et al. Candida infections in bone marrow transplant recipients. Bone Marrow Transplant 1991; 8(3): 177.
12. Bowden RA. Fungal infections after marrow transplantation. In Transplant Infections. RA Bowden, P Ljungman, and CV Paya, Ed. Philadelphia: Lippincott-Raven, 1998.
13. Wald A, Leisenring W, Van Burik JA, et al. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-1466.
14. Locksley RM, Flournoy N, Sullivan KM, et al. Infection with varicellazoster virus after marrow transplantation. Bone Marrow Transplant 1985; 152: 1172.
15. Gnann JW. Other Herpesviruses: Herpes Simplex virus, Varicella-Zoster virus, Human Herpesvirus Types 6, 7 and 8. In Transplant Infections. RA Bowden, P Ljungman, CV Paya, Ed. Philadelphia: Lippincott-Raven, 1998.
16. Ljungman P, Engelhard D, Link H, et al. Cytomegalovirus interstitial pneumonitis; Treatment with ganciclovir and intravenous immune globulin. EBMT experience. Clin Infect Dis 1992; 14: (4) 831-835.
17. Gentile G, Micozzi A, Girmenia C, et al. Pneumonia in allogeneic and autologous bone marrow recipients: a retrospective study. Chest 1993; 104(2): 371.
18. Prentice HG, Glücman E, Powles RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994; 343: 749.
19. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992; 10: 267.
20. Sepkowitz KA. Pneumocystis carinii pneumonia in patients without AIDS. Clin Infect Dis 1993; 17(Suppl 2): S416.
21. Derouin F, Devergie A, Auber P, et al. Toxoplasmosis in bone marrow transplant recipients: report of seven cases and review. Clin Infect Dis 1992; 15: 267.
22. Slavin MA, Meyers JD, Remington JS, et al. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow Transplant 1994; 13: 549.
23. Cordonnier C, Herbrecht R, Pico JL, et al. Cefepime-amikacin versus ceftazidime-amikacin as empiric treatment of febrile episodes in neutropenic patients: a comparative study of 353 patients. Clin Infect Dis 1997; 24: 41.
24. Cunningham I. Pulmonary infections after bone marrow transplant. Semin Respir Infect 1992; 7(2): 132.
25. Mossad SB, Avery RK, Longworth DL, et al. Infectious complications within the first year after nonmyeloablative allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28(5): 491.
26. Junghans C, Marr K, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8(9): 512.
27. Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993; 118: 495.
28. Goodrich JM, Bowden RA, Fisher L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118(3): 173.
29. Marr K, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909.
30. Hughes WT, Armstrong D, Bodey GP, et al. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730.
31. Cordonnier C, Buzyn-Lévy A, Leverger G, et al. Epidemiology and risk factors for gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003; 36: 149.
32. Engelhard D, Elishoov A, Strauss N, et al. Nosocomial coagulase-negative staphylococcal infections in bone marrow transplantation recipients with central vein catheter. Transplantation 1996; 61: 430.
33. Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295.
34. Cometta A, Kern WV, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin-tazobactam monotherapy. Clin Infect Dis 2003; 37: 382.
35. Edwards IR, et al. Harmonisation in pharmacovigilance. Drug Safety 1994; 10(2): 93.
36. Abdel-Mageed A, Graham-Pole J, Del Rosario MD, et al. Comparison of two doses of intravenous immunoglobulin after allogeneic bone marrow transplants. Bone Marrow Transplant 1999; 23: 929.
37. Winston DJ, Antin JH, Wolff SN, et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host-disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplant 2001; 28: 187.
38. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer Risk Index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000; 18(16): 3038.
39. Blot F, Cordonnier C, Buzyn A, et al. Severity of illness scores: Are they useful in neutropenic patients in hematology wards? A prospective multicenter study. Crit Care Medicine 2001; 29(11): 2125.
40. Engelhard D, Cordonnier C, Shaw PJ, et al. Early and late invasive pneumococcal infection following bone marrow and stem cell transplantation. Br J Haematol 2002; 117: 444.
41. Ribaud P, Chastang C, Latgé, JP, et al. Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation. Clin Infect Dis 1999; 28: 322.
42. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus Amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347(6): 408.
43. Martino R, Maertens J, Bretagne S, et al. Toxoplasmosis after hematopoietic stem cell transplantation. A study by the European Group for Blood and Marrow Transplantation Infectious Diseases Working Party. Clin Infect Dis 2000; 31(5): 1188.